W. Ian Lipkin

Last updated
W. Ian Lipkin
Lipkin, W. Ian (2008).jpg
Lipkin in 2008
Born (1952-11-18) 18 November 1952 (age 68)
Education University of Chicago Laboratory School
Alma mater
Scientific career
Website www.mailman.columbia.edu

Walter Ian Lipkin (born November 18, 1952) is the John Snow Professor of Epidemiology at the Mailman School of Public Health at Columbia University and a professor of Neurology and Pathology at the College of Physicians and Surgeons at Columbia University. He is also director of the Center for Infection and Immunity, an academic laboratory for microbe hunting in acute and chronic diseases. Lipkin is internationally recognized for his work with West Nile virus, SARS and COVID-19.



Lipkin was born in Chicago, Illinois, where he attended the University of Chicago Laboratory School and was president of the student board in 1969. He relocated to New York and earned his BA from Sarah Lawrence College in 1974. At Sarah Lawrence, he "felt that if I went straight into cultural anthropology after college I’d be a parasite. I’d go someplace, take information about myths and ritual, and have nothing to offer. So I decided to become a medical anthropologist and try to bring back traditional medicines. Suddenly I found myself in medical school." [1] Returning to his hometown Chicago, Lipkin earned his MD from Rush Medical College, in 1978. He then became a clinical clerk at the UCL Institute of Neurology in Queen Square, London, on a fellowship, and an intern in Medicine at University of Pittsburgh (1978–1979). He completed a residency in Medicine at University of Washington (1979–1981), and completed a residency in Neurology at University of California, San Francisco (1981–1984). He conducted postdoctoral research in microbiology and neuroscience at The Scripps Research Institute, from 1984 to 1990, under the mentorship of Michael Oldstone and Floyd Bloom. In his six years at Scripps, Lipkin became a senior research associate upon completing his postdoctoral work, and was president of the Scripps' Society of Fellows in 1987.


Lipkin has earned the reputation of a "master virus hunter" for to his speed and innovative methods of identifying new viruses, and has been lauded by National Institute of Allergy and Infectious Diseases director Dr. Anthony S. Fauci. As director of the Center for Infection and Immunity at the Mailman School of Public Health; Lipkin, from the onset of the COVID-19 pandemic, has led CII researchers collaborating with researchers at Sun Yat-sen University in China. Dr. Lipkin had also advised the Chinese government and the World Health Organization (WHO) during the 2002–2004 SARS outbreak. [2] [3] Dr. Lipkin described his own infection with the SARS-CoV-2 virus, beginning mid-March 2020, which resulted in a case of COVID-19 and necessitated his recovering from the illness at home, on the podcast This Week in Virology. [4]

Lipkin was the Louise Turner Arnold Chair in the Neurosciences [5] at the University of California, Irvine from 1990 to 2001 and was recruited shortly thereafter by Columbia University. He began his current tenure at Columbia as the founding director of the Jerome L. and Dawn Greene Infectious Disease Laboratory from 2002 to 2007, which transitioned to the John Snow Professorship he holds at present.

A physician-scientist, Lipkin is internationally recognized for his work with West Nile virus and SARS, as well as advancing pathogen discovery techniques by developing a staged strategy using techniques pioneered in his lab. These molecular biological methods, including MassTag-PCR, the GreeneChip diagnostic, and High Throughput Sequencing, are a major step towards identifying and studying new viral pathogens that emerge locally throughout the globe. A major node in a global network of investigators working to address the challenges of pathogen surveillance and discovery, Dr. Lipkin has trained over 30 internationally based scientists in these state-of-the art diagnostic techniques.

Lipkin is the director for the Center for Research in Diagnostics and Discovery (CRDD), under the NIH Centers of Excellence for Translational Research program. [6] The CRDD brings together leading investigators in microbial and human genetics, engineering, microbial ecology and public health to develop insights into mechanisms of disease and methods for detecting infectious agents, characterizing microflora and identifying biomarkers that can be used to guide clinical management. Lipkin was previously the Director of the Northeast Biodefense Center, [7] the Regional Center of Excellence in Biodefense and Emerging Infectious Diseases which comprised 28 private and public academic and public health institutions in New York, New Jersey and Connecticut. Within this consortium, his research focused on pathogen discovery, using unexplained hemorrhagic fever, febrile illness, encephalitis, and meningoencephalitis as targets. He is the Principal Investigator of the Autism Birth Cohort, a unique international program that investigates the epidemiology and basis of neurodevelopmental disorders through analyses of a prospective birth cohort of 100,000 children and their parents. The ABC is examining gene-environment-timing interactions, biomarkers and the trajectory of normal development and disease. Lipkin also directs the World Health Organization Collaborating Centre for Diagnostics in Zoonotic and Emerging Infectious Diseases, the only academic center, and one of two in the US (the other is CDC), that participates in outbreak investigation for the WHO.

Lipkin was co-chair of CDC Steering Committee of the National Biosurveillance Advisory Subcommittee (NBAS). [8] The NBAS was established in response to Homeland Security Presidential Directive 21 (HSPD-21), [9] "Public Health and Medical Preparedness."

He is Honorary Director of the Beijing Infectious Disease Center, Chair of the Scientific Advisory Board of the Institut Pasteur de Shanghai and serves on boards of the Australian Biosecurity Cooperative Research Centre for Emerging Infectious Disease, the Guangzhou Institute for Biomedicine and Health, the EcoHealth Alliance, [10] Tetragenetics, and 454 Life Sciences Corporation.

Lipkin served as a science consultant for the film Contagion. [11] The film has been praised for its scientific accuracy.

Early career

While not quite a medical anthropologist, Lipkin specializes in infectious diseases and their neurological impact. His first professional publication came in 1979 during the time of his fellowship in London as a letter to the Editor at the Archives of Internal Medicine (now JAMA Internal Medicine), where he poses a potential correlation between eosinopenia and bacteremia in diagnostic evaluations for a bacteremic patient. [12] While at UCL, he worked with John Newsom-Davis, who was utilizing plasmapheresis to better understand myasthenia gravis, a neuromuscular disease. [13]

In 1981, Lipkin began his neurology residency and worked in a local San Francisco clinic, which was about the time AIDS began to affect the local city population. Because of the social view of homosexual people at the time, very few clinicians would see patients with these symptoms. He "was watching many patients fall ill with AIDS. It took years for scientists to discover the virus responsible for the disease... 'I saw all of this, and I said, 'We have to find new and better ways to do this.'" [14] It was during this epidemic that Lipkin took the approach of looking for a virus’ genes instead of looking for antibodies in infected people as a way to speed up the diagnosis process. By the mid-1980s, Lipkin had published two papers specifically about AIDS research [15] [16] and transitioned into utilizing a more pathological approach to virus identification. He identified AIDS-associated immunological abnormalities and inflammatory neuropathy, which he showed could be treated with plasmapheresis and demonstrated early life exposure to viral infections affects neurotransmitter function.


In 1989, Lipkin was the first to identify a microbe using purely molecular tools. [17] [18] During his time as Chair at UC Irvine, Lipkin published several papers throughout the decade dissecting and interpreting bornavirus. [19] Once it was apparent the viral infections could selectively alter behavior and steady state brain levels of neurotransmitter mRNAs, the next step was to look for infectious agents which could be used as probes to map anatomic and functional domains in the central nervous system (CNS). [20]

By the mid-1990s, it was asserted that "Borna disease is a neurotropic negative-strand RNA virus that infects a wide range of vertebrate hosts," causing "an immune-mediated syndrome resulting in disturbances in movement and behavior." [21] This led to several groups across the globe working to determine if there was a link between Borna disease virus (BDV) or a related agent and human neuropsychiatric disease. [22] The group was formally called Microbiology and Immunology of Neuropsychiatric Disorders (MIND) and the multicenter, multi-national group focused on using standardized methods for clinical diagnosis and blinded laboratory assessment of BDV infection. [23] After nearly two decades of inquiry, the first blinded case-controlled study of the link between BDV and psychiatric illness [24] was completed by the researchers at Columbia University's Center for Infection and Immunity in a joint effort that concluded there is no association between the two. Lipkin noted that "it was concern over the potential role of BDV in mental illness and the inability to identify it using classical techniques that led us to develop molecular methods for pathogen discovery. Ultimately these new techniques enabled us to refute a role for BDV in human disease. But the fact remains that we gained strategies for the discovery of hundreds of other pathogens that have important implications for medicine, agriculture, and environmental health." [25]

West Nile Virus

West Nile Virus in New York West Nile Virus Image.jpg
West Nile Virus in New York

In 1999, West Nile virus was reported in two patients in Flushing Hospital Medical Center in Queens, New York. Lipkin led the team identifying West Nile virus in brain tissue of encephalitis victims in New York State [14] It was determined potential routes for the spread of West Nile virus throughout New York (and the Eastern United States) originated from predominantly mosquitoes, but also possible from infected birds or human beings. There is a high likelihood the two international airports nearby the initial reported cases were also the initial points of entry into the United States. [26] During the five years after the first reported case, Lipkin worked on a study with the National Institutes of Health (NIH) and the Wadsworth Center at the New York State Department of Health (NYSDOH) to determine how a vaccine could be developed. While they had some success with the immunization of mice with prME-LPs, [27] as of 2018, there is still no human vaccine for WNV. [28]


Sars-corona Coronaviruses 004 lores.jpg

Chinese scientists first discovered the severe acute respiratory syndrome (SARS) coronavirus in February 2003, but due to initial misinterpretation of the data, the information of the correct agent associated with SARS was suppressed and the outbreak investigation had a delayed start. Advanced hospital facilities were at the greatest risk as they were most susceptible to virus transmission, so it was the "classical gumshoe epidemiology" of "contact tracing and isolation" that brought swift action against the epidemic. [29] Lipkin was requested to assist with the investigation by Chen Zhou, vice president of the Chinese Academy of Sciences and Xu Guanhua, minister of the Ministry of Science and Technology in China to "assess the state of the epidemic, identify the gaps in science, and develop a strategy for containing the virus and reducing morbidity and mortality." [30] This brought the development of Real-time polymerase chain reaction (qPCR) technology, which essentially allowed for the detection of infection at earlier time points as the process, in this instance, targets the N gene sequence and amplify the analysis in a closed system. This markedly reduces the risk of contamination during processing. [31] Test kits were developed with this PCR-based assay analysis [32] and 10,000 were hand-delivered to Beijing during the height of the outbreak by Lipkin, whereupon he trained local clinical microbiologists on the proper usage. He became ill upon his return to the U.S. and was quarantined. [33]

Lipkin was asked to join the Defense Science Board Task Force on SARS Quarantine Guidance during the height of the SARS outbreak between 2003 and 2004, to advise the U.S. Department of Defense on steps to domestically manage the epidemic. As part of the EcoHealth Alliance, Lipkin's center worked in conjunction with an NIH/NIAID grant [34] assessing bats as the reservoir for the SARS virus. 47 publications resulted from this grant, which also included assessment on Nipah, Hendra, Ebola, and Marburg viruses. This proved to be significant research on the overall study of viral reservoirs as it was determined that bats carry coronaviruses and either directly infect humans with an exchange of bodily fluid (such as a bite) or indirectly by infecting an intermediate host, such as swine. [35] Lipkin addressed a health forum in Guangzhou in January 2004 where China Daily reported him as saying: "SARS virus is probably rooted and spread by rats." [36]

In 2016, the Chinese government awarded him the International Science and Technology Cooperation Award, the nation's top science honor for foreign scientists, [37] and in January 2020, it awarded him a medal marking the People's Republic of China's 70th Anniversary, both awards for his work during the 2002–2004 SARS outbreak and in strengthening China's public health system. [38]


Middle East respiratory syndrome (MERS) was first reported in Saudi Arabia during June 2012 when a local man was initially diagnosed with acute pneumonia and later died of kidney failure. The early reports of the disease were similar to SARS as the symptoms are similar, but it was quickly determined these cases were caused by a new strain called MERS coronavirus (MERS-CoV). Given Lipkin's expertise with the SARS outbreak in China nearly ten years prior, the Saudi Arabian Ministry of Health granted Lipkin and his lab local access to animal samples related to the initial reported cases. [39] With the rare opportunity, Lipkin's team created a mobile lab able to fit in six pieces of personal luggage and was transported from New York to Saudi Arabia via commercial flight to complete the analysis of samples. [40]

It seemed unlikely that bats were directly infecting humans, as the direct physical interaction between the two is limited at best. [39] A study was completed in more local proximity, examining the diverse bat populations in southeastern Mexico and determining how diverse the viruses they carry could be. [41] However, it became apparent that dromedary camels were the intermediary in the transmission between bats and humans, since camel milk and meat are dietary staples in the Saudi Arabian region. [42] The instances of human-to-human transmission appeared to be isolated to case-patients and anyone in close direct contact with them, as opposed to a broad open-air transmission. [43] By 2017, it was determined that bats are most likely the evolutionary original source for MERS-CoV along with several other coronaviruses, though not all of those types of zoonotic viruses are direct threats to humans like MERS-CoV [44] and "[c]ollectively, these examples demonstrate that the MERS-related coronaviruses are high associated with bats and are geographically widespread." [45]

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic condition characterized by extreme fatigue after exertion that is not relieved by rest and includes other symptoms, such as muscle and joint pain and cognitive dysfunction. In September 2017, the NIH awarded a $9.6 million grant to Columbia University for the "CfS for ME/CFS" intended for the pursuit of basic research and the development of tools to help both physicians and patients effectively monitor the course of the illness. [46] This collaboration effort led by Lipkin includes other institutions, such as the Bateman Horne Center (Lucinda Bateman), Harvard University (Anthony L. Komaroff), Stanford University (Kegan Moneghetti), Sierra Internal Medicine (Daniel Peterson), University of California, Davis (Oliver Fiehn), and Albert Einstein College of Medicine (John Greally), along with private clinicians in New York City. [47]

The team of researchers and clinicians initially collaborated to de-link xenotropic murine leukemia virus-related virus (XMRV) to ME/CFS after the NIH requested research into the conflicting reports between XMRV and ME/CFS. The group "consolidated its vision with support from the Hutchins Family Foundation Chronic Fatigue Initiative (CFI) and a crowd-funding organization, The Microbe Discovery Project, to explore the role of infection and immunity in disease and identify biomarkers for diagnosis through functional genomic, proteomic, and metabolomic discovery." [48] The project will collect a large clinical database and sample repository representing oral, fecal, and blood samples from well-characterized ME/CFS subjects and frequency-matched controls collected nationwide over a period of several years. Additionally, researchers are working with ME/CFS community and advocacy groups as the project progresses. [49]

Acute flaccid myelitis (AFM)

Acute flaccid myelitis (AFM) is a serious condition of the spinal cord with symptoms including rapid onset of arm or leg weakness, decreased reflexes, difficulty moving the eyes, speaking, or swallowing may also occur. Occasionally numbness or pain may be present and complications can include trouble breathing. In August 2019, Lipkin and Dr. Nischay Mishra published a collaborative study with the CDC in analyzing serological data for serum and cerebrospinal fluid (CSF) samples of AFM patients. [50] The Lipkin team utilized high-density peptide arrays (also known as Serochips) to identify antibodies to EV-D68 in those samples. The technology was featured on the Dr. Oz Show in mid-September, illustrating how the enterovirus affects the CSF and the actual Serochip used to do the analysis. [51] [52] In October, the University of California, San Francisco published a separate collaborative study with the CDC that confirmed the presence of antibodies to enterovirus in AFM patient CSF samples using phage display (VirScan). [53] "It's always good to see reproducibility. It gives more confidence in the findings for sure," commented Lipkin in an October 2019 CNN article. "This gives us more support of what we found." [54] [55] [56]


According to the Financial Times , Lipkin first learnt of COVID-19 from contacts in China, where it first emerged, in mid-December, and in early January he repeatedly urged his Chinese counterparts to publish the virus's genetic sequencing to aid research, and visited senior Chinese officials, including Premier Li Keqiang, [57] to discuss the disease. [58]

On January 29, 2020, Lipkin flew into Guangzhou, China to learn about the outbreak of SARS-CoV-2. [59] Lipkin met with the epidemiologist and pulmonologist Zhong Nanshan, [60] the lead advisor to the Chinese government during the outbreak. [61] Lipkin also worked with the China CDC to access blood samples from across the country for further study into the origin and spread of the virus. [62] Lipkin did not travel to Wuhan, the epicenter of the outbreak, due to fears that this would prevent him from returning to the United States. [63] On returning to the United States, Lipkin self-quarantined for 14 days. [64] Lipkin later contracted SARS-CoV-2 in New York City, [65] refusing to go to hospital and treating himself with hydroxychloroquine at home. [58]

Lipkin criticized what he considered a xenophobic response that blames China for the virus, specifically the words of US president Donald Trump calling it the "China virus" and his decision to suspend funding to the World Health Organization for being "China-centric", calling for "global problems" to be addressed by "global solutions". He said that a series of government missteps helped spread the virus around the world very rapidly, and criticized the US and UK's responses, calling them slow, and blamed insufficient and inadequate testing and tracing for rising fatality numbers. In the US, he singled out as an issue what he saw as an inconsistency in advice, including by president Trump, and highlighted the need for national leadership, while acknowledging states had the ability to make decisions in certain areas. He praised his NIAID superior Anthony Fauci for his integrity. He also warned about the danger of future emergence of new deadly viruses. [58]

After his trip to China, Lipkin maintained links with Lu Jiahai, his research partner at Sun Yat-sen University in Guangzhou, and Zhong Nanshan, to try to establish the origins of the virus. [60] Their efforts, aimed at finding out whether the virus emerged in other parts of China and circulated before it was first discovered in Wuhan in December, include antibody tests of nationwide blood bank samples from pneumonia patients which predate the pandemic, which led to a collaboration with the Chinese Centers for Disease Control and Prevention. [57] According to Lipkin, this research began in early February. The international research team also began studying blood samples from different wild animals which it deemed potential origins of the virus, in order to understand animal-to-human transmission. [57]

Lipkin thinks the virus could have originated in the wild animal trade and undergone “repeated jumps” from animal to human in the weeks before the first cases were logged, such a stream of events having recent precedents in the emergence of MERS-CoV, which jumped from dromedary camels to humans in 2012, and SARS-CoV, from civet cats to humans in 2003. [58]

Lipkin co-authored a paper on "The proximal origin of SARS-CoV-2", which was published in Nature Medicine in March 2020. [66]

Views on gain-of-function research

Gain-of-function (GoF) experiments aim to increase the virulence and/or transmissibility of pathogens, in order to better understand them and inform public health preparedness efforts. [67]   This includes targeted genetic modification (to create hybrid viruses), the serial passaging of a virus through a host animal (to generate adaptive mutations), and targeted mutagenesis (to introduce mutations). [68] Lipkin is a listed “supporter” of GoF advocate group, Scientists for Science, [69] which was co-founded by Columbia colleague Vincent Racaniello. [70] The US National Institutes of Health placed a moratorium on GoF research in October 2014, and lifted the moratorium in December 2017, after the implementation of stricter controls. [71] [72]

Lipkin, while not endorsing every GoF experiment, has said that "[t]here clearly are going to be instances where gain-of-function research is necessary and appropriate." In the example of Ebola, which is incapable of airborne transfer, Lipkin believes that "researchers could make a case for the need to determine how the virus could evolve in nature by engineering a more dangerous version in the lab." Lipkin believes that there should be guidelines in place to govern GoF experiments. [73] Lipkin has called for the World Health Organization to establish strict biocontainment criteria that can be applied globally - including in the developing world - to GoF research. [74]

Selected awards and honors

2020PRC 70th Anniversary Medal [38] Chinese Central Government, Central Military Commission, and State Council
2016China International Science and Technology Cooperation Award [75] People's Republic of China
2015Fellow [76] Infectious Diseases Society of America (IDSA)
2010Member [77] Association of American Physicians (AAP)
2008 John Snow Professor of Epidemiology [76] Columbia University
2006Fellow [77] American Society for Microbiology (ASM)
2004Fellow [77] New York Academy of Sciences
2003Special Advisor to the Ministry of Science and Technology [78] People's Republic of China
1986-87President, Society of Fellows [79] Scripps Research Institute

Related Research Articles

Severe acute respiratory syndrome Disease caused by severe acute respiratory syndrome coronavirus

Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by severe acute respiratory syndrome coronavirus, the first identified strain of the SARS coronavirus species severe acute respiratory syndrome–related coronavirus (SARSr-CoV). The syndrome caused the 2002–2004 SARS outbreak. Around late 2017, Chinese scientists traced the virus through the intermediary of Asian palm civets to cave-dwelling horseshoe bats in Xiyang Yi Ethnic Township, Yunnan.

Coronavirus Subfamily of viruses in the family Coronaviridae

Coronaviruses are a group of related RNA viruses that cause diseases in mammals and birds. In humans and birds, they cause respiratory tract infections that can range from mild to lethal. Mild illnesses in humans include some cases of the common cold, while more lethal varieties can cause SARS, MERS and COVID-19. In cows and pigs they cause diarrhea, while in mice they cause hepatitis and encephalomyelitis.

Severe acute respiratory syndrome coronavirus 1 Virus that causes SARS

Severe acute respiratory syndrome coronavirus 1 is a strain of coronavirus that causes severe acute respiratory syndrome (SARS), the respiratory illness responsible for the 2002–2004 SARS outbreak. It is an enveloped, positive-sense, single-stranded RNA virus which infects the epithelial cells within the lungs. The virus enters the host cell by binding to angiotensin-converting enzyme 2. It infects humans, bats, and palm civets.

EcoHealth Alliance is a US-based non-governmental organization with a stated mission of protecting people, animals, and the environment from emerging infectious diseases. The nonprofit is focused on research that aims to prevent pandemics and promote conservation in hotspot regions worldwide.

An emergent virus is a virus that is either newly appeared, notably increasing in incidence/geographic range or has the potential to increase in the near future. Emergent viruses are a leading cause of emerging infectious diseases and raise public health challenges globally, given their potential to cause outbreaks of disease which can lead to epidemics and pandemics. As well as causing disease, emergent viruses can also have severe economic implications. Recent examples include the SARS-related coronaviruses, which have caused the 2002-2004 outbreak of SARS (SARS-CoV-1) and the 2019–21 pandemic of COVID-19 (SARS-CoV-2). Other examples include the human immunodeficiency virus which causes HIV/AIDS; the viruses responsible for Ebola; the H5N1 influenza virus responsible for avian flu; and H1N1/09, which caused the 2009 swine flu pandemic. Viral emergence in humans is often a consequence of zoonosis, which involves a cross-species jump of a viral disease into humans from other animals. As zoonotic viruses exist in animal reservoirs, they are much more difficult to eradicate and can therefore establish persistent infections in human populations.

Mady Hornig American psychiatrist

Mady Hornig is an American psychiatrist and an associate professor of epidemiology at Columbia University's Mailman School of Public Health. A physician-scientist, her research involves clinical, epidemiological, and animal model research on autism and related neurodevelopmental conditions. She directs the clinical core of an international investigation of the role of Borna disease virus in human mental illness and participates as a key investigator for the Autism Birth Cohort (ABC) project, a large prospective epidemiological study, based in Norway, that is identifying how genes and timing interact with environmental agents preceding the onset of autism spectrum diagnoses. In 2006, she was appointed as Guest Professor at the School of Basic Medical Science of Beijing University in Beijing, China.

Professor Malik Peiris FRS, d'Honneur, is a Sri Lankan pathologist and virologist. He has been long based in Hong Kong. His research interests include ecology, evolution, pathogenesis, epidemiology of animal-human influenza and other human respiratory viral infections, authoring over 320 research publications. Peiris is most notable for being the first person to isolate SARS virus.

<i>Middle East respiratory syndrome–related coronavirus</i> species of virus

Middle East respiratory syndrome–related coronavirus (MERS-CoV), or EMC/2012 (HCoV-EMC/2012), is the virus that causes Middle East respiratory syndrome (MERS). It is a species of coronavirus which infects humans, bats, and camels. The infecting virus is an enveloped, positive-sense, single-stranded RNA virus which enters its host cell by binding to the DPP4 receptor. The species is a member of the genus Betacoronavirus and subgenus Merbecovirus.

Middle East respiratory syndrome Viral respiratory infection

Middle East respiratory syndrome (MERS), also known as camel flu, is a viral respiratory infection caused by Middle East respiratory syndrome–related coronavirus (MERS-CoV). Symptoms may range from none, to mild, to severe. Typical symptoms include fever, cough, diarrhea, and shortness of breath. The disease is typically more severe in those with other health problems.

MERS coronavirus EMC/2012 is a strain of coronavirus isolated from the sputum of the first person to become infected with what was later named Middle East respiratory syndrome–related coronavirus (MERS-CoV), a virus that causes Middle East respiratory syndrome (MERS).

Daniel R. Lucey is an American physician, researcher, senior scholar and adjunct professor of infectious diseases at Georgetown University, and a research associate in anthropology at the Smithsonian National Museum of Natural History, where he has co-organised an exhibition on eight viral outbreaks.

Severe acute respiratory syndrome coronavirus 2 Virus that causes COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), also known as the coronavirus, is the virus that causes COVID-19, the respiratory illness responsible for the ongoing COVID-19 pandemic. The virus was previously referred to by its provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019. First identified in the city of Wuhan, Hubei, China, the World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans. As described by the US National Institutes of Health, it is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak.

Wuhan Institute of Virology Research Institute in Wuhan, Hubei, China

The Wuhan Institute of Virology, Chinese Academy of Sciences is a research institute on virology administered by the Chinese Academy of Sciences (CAS), which reports to the State Council of the People's Republic of China. The institute is one of nine independent organisations in the Wuhan Branch of the CAS. Located in Jiangxia District, Wuhan, Hubei, it opened mainland China's first biosafety level 4 (BSL-4) laboratory. The institute has collaborated with the Galveston National Laboratory in the United States, the Centre International de Recherche en Infectiologie in France, and the National Microbiology Laboratory in Canada. The institute has been an active premier research center for the study of coronaviruses.

COVID-19 Contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic.

Kizzmekia Corbett American immunologist

Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is the Shutzer Assistant Professor at the Harvard Radcliffe Institute and assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. She joined Harvard following six years at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, National Institutes of Health based in Bethesda, Maryland. She earned a PhD in microbiology and immunology from the University of North Carolina at Chapel Hill in 2014. Appointed to the VRC in 2014, Corbett was the scientific lead of the VRC's Coronavirus Team, with research efforts aimed at propelling novel coronavirus vaccines, including a COVID-19 vaccine. In February 2021, Corbett was highlighted in the Time's "Time100 Next" list under the category of Innovators, with a profile written by Anthony Fauci.

Allison McGeer is a Canadian infectious disease specialist in the Sinai Health System, a Professor at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air.

Peter Daszak British-American zoologist

Peter Daszak is a British zoologist, consultant and public expert on disease ecology, in particular on zoonosis. He is the president of EcoHealth Alliance, a nonprofit non-governmental organization that supports various programs on global health and pandemic prevention. He is also a member of the Center for Infection and Immunity at the Columbia University Mailman School of Public Health. Daszak was involved in investigations into the initial outbreak which eventually developed into the COVID-19 pandemic and became a member of the World Health Organization team sent to investigate the origins of the COVID-19 pandemic in China. This became controversial due to Daszak's previous activities with the Wuhan Institute of Virology, perceived by some as a conflict of interest.

Transmission of COVID-19 Mechanisms that spread coronavirus disease 2019

The transmission of COVID-19 is the passing of coronavirus disease 2019 from person to person. The disease is mainly transmitted via the respiratory route when people inhale droplets and small airborne particles that infected people exhale as they breathe, talk, cough, sneeze, or sing. Infected people are more likely to transmit COVID-19 when they are physically close. However, infection can occur over longer distances, particularly indoors. 2).

History of coronavirus

The history of coronaviruses is a reflection of the discovery of the diseases caused by coronaviruses and identification of the viruses. It starts with the first report of a new type of upper-respiratory tract disease among chickens in North Dakota, U.S., in 1931. The causative agent was identified as a virus in 1933. By 1936, the disease and the virus were recognised as unique from other viral disease. They became known as infectious bronchitis virus (IBV), but later officially renamed as Avian coronavirus.

Bat coronavirus RaTG13 is a SARS-like betacoronavirus that infects the horseshoe bat Rhinolophus affinis. It was discovered in 2013 in bat droppings from a mining cave near the town of Tongguan in Mojiang county in Yunnan, China. Recent research suggests that BANAL-52, a strain of coronavirus found in bats in Laos is a closer match to SARS-CoV-2 than RaTG13 is.


  1. "Ian Lipkin The Virus Hunter" (PDF). Discover. April 2012.
  2. Zimmer, Carl (November 22, 2010). "A Man From Whom Viruses Can't Hide". The New York Times . Retrieved March 24, 2020.
  3. Kim, Elizabeth (February 3, 2020). "NYC Team Led By Scientist Who Advised On "Contagion" Is Racing To Unlock The Coronavirus. Here's What They Told Us". Gothamist . New York Public Radio. Archived from the original on February 4, 2020. Retrieved March 24, 2020.
  4. This Week in Virology (TWiV) podcast.28 March 2020 http://www.microbe.tv/twiv/twiv-special-lipkin/
  5. Gewertz, Catherine (March 31, 1993). "Realtor to Give $1.62 Million for UCI Chair". Los Angeles Times.
  6. "Centers of Excellence for Translational Research". nih.gov.
  7. "Northeast Biodefense Center". njms.rutgers.edu. Rutgers New Jersey Medical School. Retrieved August 28, 2021.
  8. "Dr. W. Ian Lipkin Named Co-Chair of CDC Subcommittee". 15 July 2010.
  9. "Homeland Security Presidential Directive". archives.gov. 18 October 2007.
  10. "Home - EcoHealth Alliance". ecohealthalliance.org.
  11. "Five Questions for Ian Lipkin, the Scientist Who Designed Contagion's Virus". 9 September 2011.
  12. Lipkin, W. I (April 1979). "Eosinophil Counts in Bacteremia" (PDF). Archives of Internal Medicine. 139 (4): 490–1. doi:10.1001/archinte.1979.03630410094035. PMID   435009.
  13. Hamblin, Terry (1998). "Plasmapheresis" . Encyclopedia of Immunology. pp.  1969–1971. doi:10.1006/rwei.1999.0495. ISBN   9780122267659.
  14. 1 2 Zimmer, Carl (November 22, 2010). "A Man From Whom Viruses Can't Hide". New York Times.
  15. Landay, A; Poon, M. C; Abo, T; Stagno, S; Lurie, A; Cooper, M. D (1983). "Immunologic studies in asymptomatic hemophilia patients. Relationship to acquired immune deficiency syndrome (AIDS)" (PDF). The Journal of Clinical Investigation. 71 (5): 1500–4. doi:10.1172/JCI110904. PMC   437015 . PMID   6222070.
  16. Lipkin, W. I; Parry, G; Kiprov, D; Abrams, D (1985). "Inflammatory neuropathy in homosexual men with lymphadenopathy" (PDF). Neurology. 35 (10): 1479–83. doi:10.1212/WNL.35.10.1479. PMID   2993951. S2CID   6542995.
  17. Lipkin, W. I; Travis, G. H; Carbone, K. M; Wilson, M. C (1990). "Isolation and characterization of Borna disease agent cDNA clones". Proceedings of the National Academy of Sciences of the United States of America. 87 (11): 4184–8. Bibcode:1990PNAS...87.4184L. doi: 10.1073/pnas.87.11.4184 . JSTOR   2354914. PMC   54072 . PMID   1693432.
  18. Lipkin, W. I (2010). "Microbe hunting". Microbiology and Molecular Biology Reviews. 74 (3): 363–77. doi:10.1128/MMBR.00007-10. PMC   2937520 . PMID   20805403.
  19. "1990 - 1999 | Columbia Public Health". www.publichealth.columbia.edu.
  20. Lipkin, W. I; Carbone, K. M; Wilson, M. C; Duchala, C. S; Narayan, O; Oldstone, M. B (1988). "Neurotransmitter abnormalities in Borna disease". Brain Research. 475 (2): 366–70. doi:10.1016/0006-8993(88)90627-0. PMID   2905625. S2CID   8893525.
  21. Briese, T; Schneemann, A; Lewis, A. J; Park, Y. S; Kim, S; Ludwig, H; Lipkin, W. I (1994). "Genomic organization of Borna disease virus". Proceedings of the National Academy of Sciences of the United States of America. 91 (10): 4362–6. Bibcode:1994PNAS...91.4362B. doi: 10.1073/pnas.91.10.4362 . PMC   43785 . PMID   8183914.
  22. Bode, L; Ludwig, H (2003). "Borna Disease Virus Infection, a Human Mental-Health Risk". Clinical Microbiology Reviews. 16 (3): 534–545. doi:10.1128/CMR.16.3.534-545.2003. PMC   164222 . PMID   12857781.
  23. Lipkin, W. I; Hornig, M; Briese, T (2001). "Borna disease virus and neuropsychiatric disease--a reappraisal". Trends in Microbiology. 9 (7): 295–8. doi:10.1016/S0966-842X(01)02071-6. PMID   11435078.
  24. Hornig, M; Briese, T; Licinio, J; Khabbaz, R. F; Altshuler, L. L; Potkin, S. G; Schwemmle, M; Siemetzki, U; Mintz, J; Honkavuori, K; Kraemer, H. C; Egan, M. F; Whybrow, P. C; Bunney, W. E; Lipkin, W. I (2012). "Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder". Molecular Psychiatry. 17 (5): 486–93. doi:10.1038/mp.2011.179. PMC   3622588 . PMID   22290118.
  25. "Does Borna Disease Virus Cause Mental Illness? | Columbia Public Health". www.publichealth.columbia.edu. January 31, 2012.
  26. Briese, T; Jia, X. Y; Huang, C; Grady, L. J; Lipkin, W. I (1999). "Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis". Lancet. 354 (9186): 1261–2. doi:10.1016/S0140-6736(99)04576-6. PMID   10520637. S2CID   5469505.
  27. Qiao, M; Ashok, M; Bernard, K. A; Palacios, G; Zhou, Z. H; Lipkin, W. I; Liang, T. J (2004). "Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells". The Journal of Infectious Diseases. 190 (12): 2104–8. doi: 10.1086/425933 . PMID   15551208.
  28. "Centers for Disease Control and Prevention: West Nile Virus". 3 June 2020.
  29. Lipkin, W. Ian (2009). "SARS: How a global epidemic was stopped". Global Public Health. 4 (5): 500–501. doi:10.1080/17441690903061389. S2CID   71513132.
  30. "Ian Lipkin Receives Top Science Honor in China | Columbia Public Health". www.publichealth.columbia.edu.
  31. Zhai, J; Briese, T; Dai, E; Wang, X; Pang, X; Du, Z; Liu, H; Wang, J; Wang, H; Guo, Z; Chen, Z; Jiang, L; Zhou, D; Han, Y; Jabado, O; Palacios, G; Lipkin, W. I; Tang, R (2004). "Real-time polymerase chain reaction for detecting SARS coronavirus, Beijing, 2003". Emerging Infectious Diseases. 10 (2): 300–3. doi:10.3201/eid1002.030799. PMC   3322935 . PMID   15030701.
  32. "Columbia University Technology Ventures, submission date April 15, 2003".
  33. "W. Ian Lipkin, MD | Columbia Public Health". www.mailman.columbia.edu.
  34. "Risk of Viral Emergence from Bats - Dimensions". app.dimensions.ai.
  35. Quan, P. L; Firth, C; Street, C; Henriquez, J. A; Petrosov, A; Tashmukhamedova, A; Hutchison, S. K; Egholm, M; Osinubi, M. O; Niezgoda, M; Ogunkoya, A. B; Briese, T; Rupprecht, C. E; Lipkin, W. I (2010). "Identification of a severe acute respiratory syndrome coronavirus-like virus in a leaf-nosed bat in Nigeria". mBio. 1 (4). doi:10.1128/mBio.00208-10. PMC   2975989 . PMID   21063474.
  36. "Back on SARS standby". www.chinadaily.com.cn. Retrieved 2020-06-12.
  37. "Ian Lipkin Receives Top Science Honor in China | Columbia Public Health". www.publichealth.columbia.edu. Mailman School of Public Health, Columbia University. January 8, 2016. Retrieved 2020-11-24.
  38. 1 2 "China Honors Ian Lipkin | Columbia Public Health". www.publichealth.columbia.edu. Mailman School of Public Health, Columbia University. January 7, 2020. Retrieved 2020-11-24.
  39. 1 2 "Bat Out of Hell? Egyptian Tomb Bat May Harbor MERS Virus". 22 August 2013.
  40. "Meet the World's Top Virus Hunter". Gizmodo.
  41. Anthony, S. J; Ojeda-Flores, R; Rico-Chávez, O; Navarrete-Macias, I; Zambrana-Torrelio, C. M; Rostal, M. K; Epstein, J. H; Tipps, T; Liang, E; Sanchez-Leon, M; Sotomayor-Bonilla, J; Aguirre, A. A; Ávila-Flores, R; Medellín, R. A; Goldstein, T; Suzán, G; Daszak, P; Lipkin, W. I (2013). "Coronaviruses in bats from Mexico". The Journal of General Virology. 94 (Pt 5): 1028–1038. doi:10.1099/vir.0.049759-0. PMC   3709589 . PMID   23364191.
  42. "Will MERS become a global threat?". 20 May 2014.
  43. Memish, Z. A; Mishra, N; Olival, K. J; Fagbo, S. F; Kapoor, V; Epstein, J. H; Alhakeem, R; Durosinloun, A; Al Asmari, M; Islam, A; Kapoor, A; Briese, T; Daszak, P; Al Rabeeah, A. A; Lipkin, W. I (2013). "Middle East respiratory syndrome coronavirus in bats, Saudi Arabia". Emerging Infectious Diseases. 19 (11): 1819–23. doi:10.3201/eid1911.131172. PMC   3837665 . PMID   24206838.
  44. Anthony, S. J; Gilardi, K; Menachery, V. D; Goldstein, T; Ssebide, B; Mbabazi, R; Navarrete-Macias, I; Liang, E; Wells, H; Hicks, A; Petrosov, A; Byarugaba, D. K; Debbink, K; Dinnon, K. H; Scobey, T; Randell, S. H; Yount, B. L; Cranfield, M; Johnson, C. K; Baric, R. S; Lipkin, W. I; Mazet, J. A (2017). "Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus". mBio. 8 (2). doi:10.1128/mBio.00373-17. PMC   5380844 . PMID   28377531.
  45. "MERS-like coronavirus identified in Ugandan bat: New virus not likely to spread to humans". ScienceDaily.
  46. "NIH Awards $9.6 Million Grant to Columbia for a Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Collaborative Research Center | Columbia Public Health". www.publichealth.columbia.edu.
  47. "Who We Are | Columbia Public Health". www.publichealth.columbia.edu.
  48. "Center for Solutions for ME/CFS". reporter.nih.gov. Retrieved August 28, 2021.
  49. "NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research | National Institute of Neurological Disorders and Stroke". www.ninds.nih.gov.
  50. Mishra, N; Ng, TFF; Marine, RL; Jain, K; Ng, J; Thakkar, R; Caciula, A; Price, A; Garcia, JA; Burns, JC; Thakur, KT; Hetzler, KL; Routh, JA; Konopka-Anstadt, JL; Nix, WA; Tokarz, R; Briese, T; Oberste, MS; Lipkin, WI (13 August 2019). "Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis". mBio. 10 (4): e01903-19. doi:10.1128/mBio.01903-19. PMC   6692520 . PMID   31409689.
  51. "Hear Firsthand From the Doctor Who is Getting Closer to Finding a Cure for AFM". The Dr. Oz Show. 16 September 2019. Retrieved 12 November 2019.
  52. "How Researchers Figured Out What Causes AFM". The Dr. Oz Show. 16 September 2019. Retrieved 12 November 2019.
  53. Schubert, RD; Hawes, IA; Ramachandran, PS; Ramesh, A; Crawford, ED; Pak, JE; Wu, W; Cheung, CK; O'Donovan, BD; Tato, CM; Lyden, A; Tan, M; Sit, R; Sowa, GA; Sample, HA; Zorn, KC; Banerji, D; Khan, LM; Bove, R; Hauser, SL; Gelfand, AA; Johnson-Kerner, BL; Nash, K; Krishnamoorthy, KS; Chitnis, T; Ding, JZ; McMillan, HJ; Chiu, CY; Briggs, B; Glaser, CA; Yen, C; Chu, V; Wadford, DA; Dominguez, SR; Ng, TFF; Marine, RL; Lopez, AS; Nix, WA; Soldatos, A; Gorman, MP; Benson, L; Messacar, K; Konopka-Anstadt, JL; Oberste, MS; DeRisi, JL; Wilson, MR (21 October 2019). "Pan-viral serology implicates enteroviruses in acute flaccid myelitis". Nature Medicine. 25 (11): 1748–1752. doi:10.1038/s41591-019-0613-1. PMC   6858576 . PMID   31636453.
  54. "Virus could be the cause of mysterious polio-like illness AFM, study says". CNN Health. 21 October 2019. Retrieved 12 November 2019.
  55. "What Causes a Mysterious Paralysis in Children? Researchers Find Viral Clues". The New York Times. 21 October 2019. Retrieved 12 November 2019.
  56. "Evidence links poliolike disease in children to a common type of virus". Science Magazine. 21 October 2019. Retrieved 12 November 2019.
  57. 1 2 3 Manson, Katrina; Sun, Yu (April 27, 2020). "US and Chinese researchers team up for hunt into Covid origins". Financial Times . Retrieved 2020-11-22.
  58. 1 2 3 4 Manson, Katrina (April 17, 2020). "Virologist behind 'Contagion' film criticises leaders' slow responses". Financial Times . Washington. Retrieved 2020-11-24.
  59. Weintraub, Karen (12 February 2020). "Epidemiologist Veteran of SARS and MERS Shares Coronavirus Insights after China Trip". Scientific American. Retrieved 16 June 2020.
  60. 1 2 Guo, Rui; Zhuang, Pinghui (2020-05-27). "Covid-19 origin research hit by political agendas: 'Sars hero'". South China Morning Post . Guangzhou and Beijing. Retrieved 2020-11-24.
  61. "Our Experts Respond to the Coronavirus Outbreak". 4 February 2020. Retrieved 2 July 2020.
  62. Manson, Katrina; Yu, Sun (27 April 2020). "US and Chinese researchers team up for hunt into Covid origins". Financial Times. Retrieved 16 June 2020.
  63. Stankiewicz, Kevin (10 February 2020). "Scientists worry coronavirus could evolve into something worse than flu, says quarantined expert". CNBC. Retrieved 2 July 2020.
  64. Paumgarten, Nick (1 March 2020). "A Local Guide to the Coronavirus". The New Yorker. Retrieved 2 July 2020.
  65. Stankiewicz, Kevin (31 March 2020). "Infectious disease expert who has coronavirus says public health can not be overlooked again". CNBC. Retrieved 2 July 2020.
  66. Andersen, Kristian G.; Rambaut, Andrew; Lipkin, W. Ian (March 17, 2020). "The proximal origin of SARS-CoV-2". Nature Medicine. Springer Nature Limited. 26 (4): 450–452. doi:10.1038/s41591-020-0820-9. PMC   7095063 . PMID   32284615.
  67. Selgelid, Michael J. (2016). "Gain-of-Function Research: Ethical Analysis". Science and Engineering Ethics. 22 (4): 923–964. doi:10.1007/s11948-016-9810-1. ISSN   1353-3452. PMC   4996883 . PMID   27502512.
  68. "Gryphon Report, Final Draft, Analysis of Gain-of-Function Research, Dec, 2015, p43-45" (PDF).
  69. "Scientists for Science". www.scientistsforscience.org. Retrieved 2020-06-10.
  70. Jul 30, Robert Roos | News Editor | CIDRAP News |; 2014. "Scientists voice support for research on dangerous pathogens". CIDRAP. Retrieved 2020-06-10.CS1 maint: numeric names: authors list (link)
  71. Reardon, Sara (19 December 2017). "US government lifts ban on risky pathogen research". Nature. Retrieved 2 July 2020.
  72. Burki, Talha (2018-02-01). "Ban on gain-of-function studies ends". The Lancet Infectious Diseases. 18 (2): 148–149. doi:10.1016/S1473-3099(18)30006-9. ISSN   1473-3099. PMC   7128689 . PMID   29412966.
  73. Reardon, Sara (23 October 2014). "U.S. Suspends Risky Disease Research". Nature. 514 (7523): 411–2. Bibcode:2014Natur.514..411R. doi: 10.1038/514411a . PMID   25341765. S2CID   4448945 . Retrieved 2020-06-10.
  74. Lipkin, W. Ian (2012-11-01). "Biocontainment in Gain-of-Function Infectious Disease Research". mBio. 3 (5). doi: 10.1128/mBio.00290-12 . ISSN   2150-7511. PMC   3484385 . PMID   23047747.
  75. "Ian Lipkin Receives Top Science Honor in China | Columbia Public Health". www.publichealth.columbia.edu.
  76. 1 2 "Dr. W Ian Lipkin, Center for Infection & Immunity | Columbia Public Health". www.publichealth.columbia.edu.
  77. 1 2 3 National Academies Of Sciences, Engineering; Affairs, Policy Global; Committee On Science, Technology; Management, Committee on Dual Use Research of Concern: Options for Future (2017-09-01). Dual Use Research of Concern in the Life Sciences: Current Issues and Controversies. p. 87. ISBN   9780309458917.
  78. "mBio Professional Profile: Board of Editors, W. Ian Lipkin, MD".
  79. "Oral history interview with W. Ian Lipkin". Science History Institute Digital Collections.